Suppr超能文献

单个长非编码 RNA 分子的生物工程,该分子携带多个小 RNA。

Bioengineering of a single long noncoding RNA molecule that carries multiple small RNAs.

机构信息

Department of Biochemistry & Molecular Medicine, UC Davis School of Medicine, Sacramento, CA, 95817, USA.

出版信息

Appl Microbiol Biotechnol. 2019 Aug;103(15):6107-6117. doi: 10.1007/s00253-019-09934-5. Epub 2019 Jun 11.

Abstract

Noncoding RNAs (ncRNAs), including microRNAs (miRNAs), small interfering RNAs (siRNAs), and long noncoding RNAs (lncRNAs), regulate target gene expression and can be used as tools for understanding biological processes and identifying new therapeutic targets. Currently, ncRNA molecules for research and therapeutic use are limited to ncRNA mimics made by chemical synthesis. We have recently established a high-yield and cost-effective method of producing bioengineered or biologic ncRNA agents (BERAs) through bacterial fermentation, which is based on a stable tRNA/pre-miR-34a carrier (~ 180 nt) that accommodates target small RNAs. Nevertheless, it remains a challenge to heterogeneously express longer ncRNAs (e.g., > 260 nt), and it is unknown if single BERA may carry multiple small RNAs. To address this issue, we hypothesized that an additional human pre-miR-34a could be attached to the tRNA/pre-miR-34a scaffold to offer a new tRNA/pre-miR-34a/pre-miR-34a carrier (~ 296 nt) for the accommodation of multiple small RNAs. We thus designed ten different combinatorial BERAs (CO-BERAs) that include different combinations of miRNAs, siRNAs, and antagomirs. Our data showed that all target CO-BERAs were successfully expressed in Escherichia coli at high levels, greater than 40% in total bacterial RNAs. Furthermore, recombinant CO-BERAs were purified to a high degree of homogeneity by fast protein liquid chromatography methods. In addition, CO-BERAs exhibited strong anti-proliferative activities against a variety of human non-small cell lung cancer cell lines. These results support the production of long ncRNA molecules carrying different warhead small RNAs for multi-targeting which may open avenues for developing new biologic RNAs as experimental, diagnostic, and therapeutic tools.

摘要

非编码 RNA(ncRNA),包括 microRNA(miRNA)、小干扰 RNA(siRNA)和长非编码 RNA(lncRNA),可调控靶基因的表达,并可作为了解生物过程和鉴定新治疗靶点的工具。目前,用于研究和治疗的 ncRNA 分子仅限于化学合成的 ncRNA 模拟物。我们最近建立了一种通过细菌发酵生产生物工程或生物 ncRNA 制剂(BERA)的高产、经济有效的方法,该方法基于稳定的 tRNA/miR-34a 载体(180nt),可容纳靶标小 RNA。然而,异源表达更长的 ncRNA(例如>260nt)仍然是一个挑战,并且尚不清楚单个 BERA 是否可以携带多个小 RNA。为了解决这个问题,我们假设可以将另一个人源 miR-34a 附加到 tRNA/miR-34a 支架上,提供一个新的 tRNA/miR-34a/miR-34a 载体(296nt),用于容纳多个小 RNA。因此,我们设计了十种不同的组合 BERA(CO-BERA),包括不同组合的 miRNA、siRNA 和 antagomir。我们的数据表明,所有目标 CO-BERA 都能在大肠杆菌中高水平表达,在总细菌 RNA 中的比例大于 40%。此外,重组 CO-BERA 可通过快速蛋白液相色谱法高度均一地纯化。此外,CO-BERA 对多种人非小细胞肺癌细胞系表现出强烈的抗增殖活性。这些结果支持携带不同弹头小 RNA 的长 ncRNA 分子的生产,用于多靶点靶向,这可能为开发新的生物 RNA 作为实验、诊断和治疗工具开辟途径。

相似文献

1
Bioengineering of a single long noncoding RNA molecule that carries multiple small RNAs.
Appl Microbiol Biotechnol. 2019 Aug;103(15):6107-6117. doi: 10.1007/s00253-019-09934-5. Epub 2019 Jun 11.
2
Expression and Purification of tRNA/ pre-miRNA-Based Recombinant Noncoding RNAs.
Methods Mol Biol. 2021;2323:249-265. doi: 10.1007/978-1-0716-1499-0_18.
3
fermentation production of humanized noncoding RNAs carrying payload miRNAs for targeted anticancer therapy.
Theranostics. 2021 Mar 4;11(10):4858-4871. doi: 10.7150/thno.56596. eCollection 2021.
4
Bioengineering of noncoding RNAs for research agents and therapeutics.
Wiley Interdiscip Rev RNA. 2016 Mar-Apr;7(2):186-97. doi: 10.1002/wrna.1324. Epub 2016 Jan 13.
5
Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy.
J Pharmacol Exp Ther. 2018 Jun;365(3):494-506. doi: 10.1124/jpet.118.247775. Epub 2018 Mar 30.
8
Bioengineered non-coding RNA agent (BERA) in action.
Bioengineered. 2016 Nov;7(6):411-417. doi: 10.1080/21655979.2016.1207011. Epub 2016 Jul 14.
9
Novel approaches for efficient  in vivo fermentation production of noncoding RNAs.
Appl Microbiol Biotechnol. 2020 Mar;104(5):1927-1937. doi: 10.1007/s00253-020-10350-3. Epub 2020 Jan 17.

引用本文的文献

1
Targeting Regulatory Noncoding RNAs in Human Cancer: The State of the Art in Clinical Trials.
Pharmaceutics. 2025 Apr 4;17(4):471. doi: 10.3390/pharmaceutics17040471.
2
Non-coding RNAs: emerging biomarkers and therapeutic targets in cancer and inflammatory diseases.
Front Oncol. 2025 Mar 10;15:1534862. doi: 10.3389/fonc.2025.1534862. eCollection 2025.
3
CircRNA-miRNA-VEGFA: an important pathway to regulate cancer pathogenesis.
Front Pharmacol. 2023 May 10;14:1049742. doi: 10.3389/fphar.2023.1049742. eCollection 2023.
4
Recombinant Technologies Facilitate Drug Metabolism, Pharmacokinetics, and General Biomedical Research.
Drug Metab Dispos. 2023 Jun;51(6):685-699. doi: 10.1124/dmd.122.001008. Epub 2023 Mar 22.
5
Bioengineered RNA Therapy in Patient-Derived Organoids and Xenograft Mouse Models.
Methods Mol Biol. 2022;2521:191-206. doi: 10.1007/978-1-0716-2441-8_10.
6
miR-34a-5p inhibits the malignant progression of KSHV-infected SH-SY5Y cells by targeting c-fos.
PeerJ. 2022 Apr 15;10:e13233. doi: 10.7717/peerj.13233. eCollection 2022.
7
ncRNAs in Therapeutics: Challenges and Limitations in Nucleic Acid-Based Drug Delivery.
Int J Mol Sci. 2021 Oct 27;22(21):11596. doi: 10.3390/ijms222111596.
8
Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination.
Pharmacol Ther. 2022 Feb;230:107967. doi: 10.1016/j.pharmthera.2021.107967. Epub 2021 Aug 14.
9
Noncoding RNA therapeutics - challenges and potential solutions.
Nat Rev Drug Discov. 2021 Aug;20(8):629-651. doi: 10.1038/s41573-021-00219-z. Epub 2021 Jun 18.
10
Expression and Purification of tRNA/ pre-miRNA-Based Recombinant Noncoding RNAs.
Methods Mol Biol. 2021;2323:249-265. doi: 10.1007/978-1-0716-1499-0_18.

本文引用的文献

1
Bioengineered miR-27b-3p and miR-328-3p modulate drug metabolism and disposition the regulation of target ADME gene expression.
Acta Pharm Sin B. 2019 May;9(3):639-647. doi: 10.1016/j.apsb.2018.12.002. Epub 2018 Dec 11.
2
Bioengineered Let-7c Inhibits Orthotopic Hepatocellular Carcinoma and Improves Overall Survival with Minimal Immunogenicity.
Mol Ther Nucleic Acids. 2019 Mar 1;14:498-508. doi: 10.1016/j.omtn.2019.01.007. Epub 2019 Jan 24.
3
New technologies provide more metabolic engineering strategies for bioethanol production in Zymomonas mobilis.
Appl Microbiol Biotechnol. 2019 Mar;103(5):2087-2099. doi: 10.1007/s00253-019-09620-6. Epub 2019 Jan 19.
4
Treating Disease at the RNA Level with Oligonucleotides.
N Engl J Med. 2019 Jan 3;380(1):57-70. doi: 10.1056/NEJMra1705346.
5
A genetically engineered microRNA-34a prodrug demonstrates anti-tumor activity in a canine model of osteosarcoma.
PLoS One. 2018 Dec 31;13(12):e0209941. doi: 10.1371/journal.pone.0209941. eCollection 2018.
6
RNA therapy: Are we using the right molecules?
Pharmacol Ther. 2019 Apr;196:91-104. doi: 10.1016/j.pharmthera.2018.11.011. Epub 2018 Dec 4.
7
Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models.
Cancer Lett. 2019 Feb 1;442:82-90. doi: 10.1016/j.canlet.2018.10.038. Epub 2018 Oct 30.
8
Synthetic genomics: a new venture to dissect genome fundamentals and engineer new functions.
Curr Opin Chem Biol. 2018 Oct;46:56-62. doi: 10.1016/j.cbpa.2018.04.002. Epub 2018 May 9.
9
Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy.
J Pharmacol Exp Ther. 2018 Jun;365(3):494-506. doi: 10.1124/jpet.118.247775. Epub 2018 Mar 30.
10
Bioengineered NRF2-siRNA Is Effective to Interfere with NRF2 Pathways and Improve Chemosensitivity of Human Cancer Cells.
Drug Metab Dispos. 2018 Jan;46(1):2-10. doi: 10.1124/dmd.117.078741. Epub 2017 Oct 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验